HOLLISTON, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- An archived webcast is now available of a press conference held earlier today that detailed the first successful transplant of a regenerated trachea in the United States. The press conference was held at Children's Hospital of Illinois, where the surgery took place, and where the recipient of the implant, two-year-old Hannah Genevieve Warren, is currently recovering.
The surgery was the world's first successful pediatric regenerated trachea transplant using a synthetic scaffold. This was also the first regenerated trachea transplant surgery using a scaffold manufactured by Harvard Apparatus Regenerative Technology, Inc. (HART), the wholly owned regenerative medicine technology subsidiary of Harvard Bioscience. The implant used in the procedure was grown in one of HART's "InBreath" bioreactors.
Additional details about the surgery can be found in the press release " Harvard Apparatus Regenerative Technology's 'InBreath' Scaffold and Bioreactor Used in First U.S. Transplant of a Regenerated Trachea," released earlier today.The archived webcast of the press conference is available at the following link: http://www.childrenshospitalofillinois.org/trachea-surgery/live-feed.html?utm_source=Newsletter&utm_medium=Email&utm_campaign=Trachea+Surgery++External+Communication Further, the following link leads to an NBC news video describing the landmark surgery: http://www.today.com/video/today/51716123#51716123 About Harvard Bioscience Harvard Bioscience, or HBIO, is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. HBIO sells its products to thousands of researchers in over 100 countries primarily through its 850 page catalog (and various other specialty catalogs), its website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden and Spain with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com . About Harvard Apparatus Regenerative Technology, Inc. Harvard Apparatus Regenerative Technology, Inc., a wholly owned subsidiary of Harvard Bioscience, develops and manufactures devices for use within the emerging field of regenerative medicine. These devices include bioreactors and synthetic scaffolds for growing tissue and organs outside the body; and injectors for stem cell therapy.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts